Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer

ABSTRACT: RGX-202-01 (ompenaclid) is a Phase 1, first-in-human, dose escalation and expansion study of RGX-202-01 as a single agent and in combination with FOLFIRI +/- bevacizumab. RGX-202-01 is a small molecule inhibitor of the creatine transporter SLC6a8, a novel metabolic target that drives gastrointestinal cancer progression. During the dose escalation stage, multiple doses of orally administered RGX-202-01 with or without FOLFIRI +/- bevacizumab (single agent or combination therapy) will be evaluated in patients with advanced gastrointestinal tumors (i.e., locally advanced and unresectable, or metastatic) who have had PD on available standard systemic therapies or for which there are no standard systemic therapies of relevant clinical impact. In the expansion stage: Patients with colorectal cancer (CRC) RAS Mutant will be treated at the optimal dose.

DISEASE(S): Gastrointestinal Neoplasms,Gastrointestinal Cancer,Colorectal Cancer,Kras Mutation-related Tumors,Neoplasms,Colorectal Carcinoma,Crc,Gastric Cancer,Colorectal Cancer Metastatic,Colorectal Neoplasms,Gastric Neoplasm,Stomach Neoplasms,Digestive System Neoplasms

PROVIDER: 2278491 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Epigenetic Analysis of Eµ-Myc B-cell lymphoma using both H3K27me3 CHiP-Seq and Bisulfite-Seq (reduced representation).

Project description:We used RRBS and H3K27me3 to understand epigenetic changes in resistant cell lines to DNA crosslinking agent, mafosfamide, (Parental, R100, R500, R1000, R2000, R4000) via dose escalation.

2016-03-08 | GSE78939 | GEO

Expression data from Eµ-Myc B-cell lymphoma

2014-08-13 | GSE60342 | GEO

A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer

Project description:This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in combination with FOLFIRI in patients with previously treated metastatic colorectal cancer. This study includes two stages. Stage 1 is the dose-escalation stage. Once the maximum tolerated dose (MTD) of Sevacizumab has been established, additional patients will be enrolled in the cohort-expansion stage (Stage 2).

| 2190733 | ecrin-mdr-crc

RNA-Seq to probe transcription of patient-derived organotypic colorectal cancer.

Project description:Patient-derived cancer organoids (PCOs) provide a platform to model resistant to targeted therapies. Following culture maturation, PCOs were treated with stepwise dose escalation of EGFR inhibitors. Cultures were started at 20% physiologic Cmax panitumumab (46ug/ml) and assessed for growth (normalized change in diameter at 96 hours). If cultures surpassed ≥20% growth, stepwise dose escalation was repeated with interval increase of 20% Cmax. Time to resistant (TTR) was defined by duration of time from the initiation of dose escalation to persistent growth at 100% Cmax panitumumab. All samples were collected in triplicate biological replicates at baseline and after achieving resistance to EGFRi with persistent growth at 100% physiologic Cmax. RNA library was constructed using TruSeq Stranded total RNA with rRNA reduction (Illumina). Quality control was performed by Eukaryote Total RNA electrophoresis using NanoDropOne. The library included 2x150bp paired end reads with sequencing performed by NovaSeq 6000 using MiSeq NanoCell at University of Wisconsin Biotechnology Center.

2023-07-01 | GSE180480 | GEO

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Project description:This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (CRC).

| 2207421 | ecrin-mdr-crc

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Project description:This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1 antibody, in subjects with advanced solid tumors.

| 2296301 | ecrin-mdr-crc

A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer

Project description:This is a multicenter, open-label, Phase 1 study of SC-006 given as a single agent and in combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists of Part A (single agent SC-006 dose regimen finding), followed by Part B (single agent SC-006 dose expansion), and Part C (SC-006 and ABBV-181 combination escalation and expansion). Part A (dose regimen finding) will involve dose escalation and possible dose interval modification to define the maximum tolerated dose (MTD) and/or recommended Part B dose and schedule. Part B (dose expansion) will enroll additional participants who will be treated with a study drug dose at or below the MTD determined in Part A. Part C is dose escalation of SC-006 and fixed dose of ABBV-181 in combination. Recommended dose cohort of SC-006 with ABBV-181 will be expanded.

| 2235325 | ecrin-mdr-crc

Expression data from EÂµ-Myc B-cell lymphoma

Project description:We used microarrays to understand gene expression changes in response to DNA crosslinking agent mafosfamide over a 48 hour period. We also created resistant cell lines (R100, R500, R1000, R2000, R4000) via dose escalation and used microarrays to probe expression changes between the parental and resistant cell lines. EÂµ-Myc B-cells were co-cultured in vitro with 750nM mafosfamide for 48 hours. Samples were collected at 0, 6, 12, 24, and 48 hours. Additionally, resistant lines were either treated or untreated with 750nM for 24 hours.

2014-08-13 | E-GEOD-60342 | biostudies-arrayexpress

Molecular subtypes of metastatic colorectal cancer are predictive of patient response to chemo and targeted therapies (part 2)

Project description:We report that previously described molecular subtypes of colorectal cancer are associated with the response to therapy in patients with metastatic disease. We also identified a patient population with high FOLFIRI sensitivity, as indicated by their 2.7-fold longer overall survival when treated with FOLFIRI, as first-line regimen, instead of FOLFOX. Our results demonstrate the interest of molecular classifications to develop tailored therapies for patients with metastatic colorectal cancer.

2017-08-17 | GSE72969 | GEO

Molecular subtypes of metastatic colorectal cancer are predictive of patient response to chemo and targeted therapies (part 1)

2017-08-17 | GSE72968 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data